Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
:KYTX
KYTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.78 - $7.20
Previous CloseN/A
Volume87.17K
Average Volume (3M)399.81K
Market Cap
$281.96M
Enterprise Value-$73.06M
Total Cash (Recent Filing)$211.68M
Total Debt (Recent Filing)$5.92M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 12, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding43,245,667
10 Day Avg. Volume597,799
30 Day Avg. Volume399,808
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.26
Enterprise Value/Revenue-36.10
Enterprise Value/Gross Profit34.19
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$19.75Price Target Upside213.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyData from KYV-101 demonstrates continued durable, drug-free, and disease-free remission in both stiff person syndrome and myasthenia gravis, highlighting the treatment's long-term effectiveness.
Market LeadershipKyverna is poised to have the first FDA approved CAR-T for the treatment of an autoimmune disease, which could secure the company’s position as a leader in the field.
Regulatory ProgressKyverna Therapeutics unveiled an innovative Phase 3 trial design that supports a rapid and clear path to regulatory filing in myasthenia gravis.
Bears Say
Competition And Approval ChallengesThe company's lead candidate, KYV-101, is being evaluated in a potentially registrational trial for stiff person syndrome, a rare disease with no approved therapies, indicating a significant market opportunity.
Trial EnrollmentPatient enrollment in the Phase III portion is expected to begin by the end of 2025.
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $1.78 and its highest was $7.20 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $281.96M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 47 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.044 by $0.074.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.94.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,245,667 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.044. Following the earnings report the stock price went up 14.901%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (213.00% Upside)
$19.75 (213.00% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▲ 31.1%
Last 30 Days ▲ 31.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.95%
12-Months-Change
Fundamentals
Return on Equity
-61.29%
Trailing 12-Months
Asset Growth
-37.62%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$19.75
▲(213.00% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
C4 Therapeutics
―
Aziyo Biologics
―
Vor Biopharma
―
Climb Bio
―
Ownership Overview
21.33% Insiders
8.73% Mutual Funds
35.62% Other Institutional Investors
30.90% Public Companies and Individual Investors